Safety and efficacy of teneligliptin: A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes

International Urology and Nephrology

Volumn 46, Issue 2, 2014, Pages 427-432

  Otsuki, Hideo ^a   Kosaka, Takeo ^a,b   Nakamura, Kenzo ^a   Shimomura, Fumihiko ^c   Kuwahara, Yoshitaka ^a   Tsukamoto, Takuji ^a  

^a Nagakubo Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Sanwa Clinic   (Japan)

Author keywords

Diabetes mellitus; DPP 4 inhibitor; End stage renal disease; Glycated albumin; Hemodialysis; Teneligliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; LAXATIVE; MIGLITOL; MITIGLINIDE; ORAL ANTIDIABETIC AGENT; PICOSULFATE SODIUM; TENELIGLIPTIN; VILDAGLIPTIN; VOGLIBOSE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; SIDE EFFECT; WEIGHT GAIN;

ADAMANTANE; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRILES; PROSPECTIVE STUDIES; PYRAZOLES; PYRROLIDINES; RENAL DIALYSIS; SERUM ALBUMIN; THIAZOLIDINES;

EID: 84896707203     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0552-6     Document Type: Article

References (15)

1. Bouchi R, Babazono T, Yoshida N et al (2010) Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes. Hypertens Res 33:1298-1304
2. Freedman BI, Andries L, Shihabi ZK et al (2011) Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 6:1635-1643
3. Fukuoka K, Nakao K, Morimoto H et al (2008) Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 13:278-283 (Pubitemid 351668328)
4. Inaba M, Maekawa K, Okuno S et al (2012) Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 78:273-280
5. Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R (2010) Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 5:1595-1601
6. Feldt-Rasmussen B (2006) Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int 70:1392-1394
7. Inaba M, Okuno S, Kumeda Y et al (2007) Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 18:896-903 (Pubitemid 46434506)
8. Kishimoto M (2013) Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 6:187-195
9. Peacock TP, Shihabi ZK, Bleyer AJ et al (2008) Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 73:1062-1068 (Pubitemid 351543905)
10. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13:947-954
11. Eto T, Inoue S, Kadowaki T (2012) Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 14:1040-1046
12. Regeur L, Faber OK, Binder C (1978) Plasma C-peptide in uraemic patients. Scand J Clin Lab Invest 38:771-775 (Pubitemid 9085053)
13. Robaudo C, Zavaroni I, Garibotto G, Deferrari G (1996) Renal metabolism of C-peptide in patients with early insulin-dependent diabetes mellitus. Nephron 72:395-401 (Pubitemid 26059570)
14. Gallwitz B (2007) Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs Today (Barc) 43:801-814
15. Monami M, Iacomelli I, Marchionni N, Mannucci E (2010) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a metaanalysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 20:224-235